clinical trials

News

AMPLIFY results dial up Calquence's potential in CLL

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuste

R&D

5 strategies for biopharma to optimise patient recruitment i...

Patient recruitment remains a significant challenge for biopharma companies, often leading to delays and increased costs in clinical trials.

News

ODAC unpicks AZ's Imfinzi trial in perioperative NSCLC

FDA reviewers were so frustrated by AstraZeneca's application for Imfinzi as a treatment before and after surgery for resectable non-small cell lung cancer (NSCLC) that they voted for a ret

Digital

horizon image for feature on the trends shaping the future of healthcare

DIA 2024: Charting new horizons in patient-centered R&D

In its 60th year, the Drug Information Association (DIA) global annual meeting

News

Biogen, Sage drug for essential tremor flunks mid-stage test

Biogen's $3 billion alliance with Sage Therapeutics has suffered another setback after their drug for essential tremor failed to move the needle in a phase 2 study.

News

GSK's Dovato matches rival Biktarvy with less weight gain

GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain.

AMPLIFY results dial up Calquence's potential in CLL

5 strategies for biopharma to optimise patient recruitment i...

ODAC unpicks AZ's Imfinzi trial in perioperative NSCLC

DIA 2024: Charting new horizons in patient-centered R&D

Biogen, Sage drug for essential tremor flunks mid-stage test

GSK's Dovato matches rival Biktarvy with less weight gain

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

clinical trials

Editor's Picks